Drug Profile
Research programme: therapies - Merck & Co/vTv Therapeutics
Alternative Names: Therapies research programme - Merck & Co/TransTech PharmaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics LLC
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 23 Mar 2010 Preclinical development is ongoing in USA
- 15 Sep 2004 Preclinical trials in Undefined in USA (unspecified route)